At ESC 2025, the STEER study showed semaglutide reduced risk of heart attack, stroke, or death by 57% vs tirzepatide in adults with obesity and cardiovascular disease, complementing prior trial data.
The ACC provides evidence-based guidance on improving vaccine uptake in vulnerable patients, addressing vaccine hesitancy, and improving overall vaccine access.
ESC 2025: The first global investigation of evidence for the potential positive connection is encouraging, but more research is needed to understand causality.